Based on the above understanding of the mechanism, the development of drugs targeting HIF-1α holds great promise: small-molecule compounds designed to precisely regulate its activity (such as inhibiting excessive activation) have been shown to reverse glucose metabolism disorders and inflammatory factor imbalances in LPS-induced AKI models (Li et al., 2021b). Here, HIF1A is linked to acute kidney injury.